Evidence map›Paper›PMID 41181988›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Therapeutic Reprogramming of Glioblastoma Phenotypic States Using Multifunctional Heparin Nanoparticles.

Vadim Le Joncour, Austin D Evans, Camilla Karoliina Bergström, Vignesh Kumar Rangasami, Sumanta Samanta, Nithiyanandan Krishnan, Yuji Teramura, Bo Nilsson, Patricia Hedenqvist, Elin Manell and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Nanovaccines in gastrointestinal cancers.Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Vadim Le JoncourNeuroscience Center, Helsinki Institute of Life Science and iCAN Digital Precision Medicine Flagship Program, University of Helsinki, Haartmaninkatu 8, Helsinki, 00290, Finland.ORCID https://orcid.org/0000-0001-8153-8563
Austin D EvansBioengineering and Nanomedicine Lab, Faculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 3, Tampere, 33720, Finland.ORCID https://orcid.org/0000-0003-1571-827X
Camilla Karoliina BergströmNeuroscience Center, Helsinki Institute of Life Science and iCAN Digital Precision Medicine Flagship Program, University of Helsinki, Haartmaninkatu 8, Helsinki, 00290, Finland.ORCID https://orcid.org/0009-0002-0263-4325
Vignesh Kumar RangasamiBioengineering and Nanomedicine Lab, Faculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 3, Tampere, 33720, Finland.
Sumanta SamantaBioengineering and Nanomedicine Lab, Faculty of Medicine and Health Technology, Tampere University, Korkeakoulunkatu 3, Tampere, 33720, Finland.ORCID https://orcid.org/0000-0002-1967-2232
Nithiyanandan KrishnanTranslational Chemical Biology Group, Division of Macromolecular Chemistry, Department of Chemistry-Ångström Laboratory, Uppsala University, Uppsala, SE75121, Sweden.
Yuji TeramuraCellular and Molecular Biotechnology Research Institute (CMB), National Institute of Advanced Industrial Science and Technology (AIST), AIST Tsukuba Central 5, 111 Higashi, Tsukuba, Ibaraki, 3058565, Japan.ORCID https://orcid.org/0000-0002-0709-1000
Bo NilssonDepartment of Immunology, Genetics and Pathology (IGP), Uppsala University, Dag Hammarskjölds väg 20, Uppsala, 75185, Sweden.
Patricia HedenqvistDepartment of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, 75105, Sweden.ORCID https://orcid.org/0000-0003-4540-6250
Elin ManellDepartment of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, 75105, Sweden.ORCID https://orcid.org/0000-0002-4491-7609
Jons HilbornTranslational Chemical Biology Group, Division of Macromolecular Chemistry, Department of Chemistry-Ångström Laboratory, Uppsala University, Uppsala, SE75121, Sweden.ORCID https://orcid.org/0000-0003-1339-4400
Marianne-Jensen WaernDepartment of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, 75105, Sweden.
Oommen P VargheseTranslational Chemical Biology Group, Division of Macromolecular Chemistry, Department of Chemistry-Ångström Laboratory, Uppsala University, Uppsala, SE75121, Sweden.ORCID https://orcid.org/0000-0001-8872-9928
Pirjo LaakkonenTranslational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, 00010, Finland.ORCID https://orcid.org/0000-0002-9620-095X
Oommen P OommenSchool of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 3NB, UK.ORCID https://orcid.org/0000-0003-2768-0133

Funding

Academy of Finland #321867Finnish Cultural Foundation #50251179Linnea Pirilä Fund and Aino Valvaalan FundPirkanmaan Rahasto 50241473Sigrid Juséliuksen Säätiö 240150Syöpääsäätiö Cancer Foundation FinlandTampere University Doctoral School FundUniversity of Helsinki, Doctoral Programme in Biomedicine
6 · The paper itself

Abstract

Glioblastomas (GB) are the most common and deadly primary malignant brain tumors due to their infiltrative growth and resistance to conventional therapies. GB cell plasticity and differentiation into drug-resistant mesenchymal-like (MES) states protect tumors from conventional treatments. This study introduces a novel precision medicine approach employing heparin-based nanoparticles (HP-NPs) engineered to cross the blood-brain barrier and target MES-like glioma stem cells (GSCs). Encapsulating doxorubicin (DOX) in HP-NPs reduces drug-mediated complement and coagulation cascades, enhancing hemocompatibility in human whole blood. In vitro, HP-NPs demonstrate efficient uptake by patient-derived GSCs. Preclinical evaluations in patient avatars indicate plain HP-NPs outperform DOX-loaded HP-NPs in reducing GB progression. Transcriptomic studies show HP-NPs downregulate heparin-binding epidermal growth factor (HBEGF), shifting MES GSCs into less plastic astroglial-like cells, impairing tumorigenesis. HP-NPs are well-tolerated and safe at therapeutic doses in healthy rats, offering a promising new paradigm in anticancer therapy to overcome GB recurrence and improve therapeutic outcomes.

Indexed as

Brain NeoplasmsGlioblastomaHeparinNanoparticlesAnimalsCell Line, TumorDoxorubicinHumansNeoplastic Stem CellsRatsDoxorubicinHeparinblood‐brain barrierdrug deliveryglioma stem cellsheparinnanoparticles

Identifiers

PMID41181988
PMCPMC12806396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.